Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.2%

19 terminated/withdrawn out of 117 trials

Success Rate

83.5%

-3.0% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 96 completed trials have results

Key Signals

19 withdrawn

Enrollment Performance

Analytics

Phase 1

65(60.7%)

N/A

25(23.4%)

Phase 2

16(15.0%)

Phase 4

1(0.9%)

107Total

Phase 1(65)

N/A(25)

Phase 2(16)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (117)

Showing 20 of 117 trials

NCT07005999Active Not Recruiting

Interventional Ablation for Early-stage Lung Cancer

Role: collaborator

NCT02449135Unknown

Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma

Role: lead

NCT02430675Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms

Role: lead

NCT02430610Not ApplicableCompleted

Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms

Role: lead

NCT02430636Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms

Role: lead

NCT02329106Not ApplicableCompleted

Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome

Role: lead

NCT02333773Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli

Role: lead

NCT02352935Not ApplicableCompleted

Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

Role: lead

NCT02332551Not ApplicableCompleted

Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder

Role: lead

NCT02430779Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms

Role: lead

NCT02430701Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms

Role: lead

NCT02430766Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)

Role: lead

NCT02343835Not ApplicableCompleted

Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

Role: lead

NCT04393220Phase 2Completed

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

Role: lead

NCT02335112Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms

Role: lead

NCT02335827Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Renal Tumors

Role: lead

NCT02340858Not ApplicableCompleted

Percutaneous Irreversible Electroportion for Unresectable Breast Cancer

Role: lead

NCT02430623Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms

Role: lead

NCT02425059Not ApplicableCompleted

Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms

Role: lead

NCT02430753Not ApplicableCompleted

Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency

Role: lead